139 related articles for article (PubMed ID: 36997858)
1. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.
Huang H; Tang Y; Wu D; Meng X; Wang S; Wang J; Yu Y; Fang Y; Fang H; Zhu Q; Li N; Xu B; Sun Y; He J
BMC Geriatr; 2023 Mar; 23(1):199. PubMed ID: 36997858
[TBL] [Abstract][Full Text] [Related]
2. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
3. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
4. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
5. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
6. Trend of drug clinical trials in mainland China from 2009 to 2020.
Cao Y; Liao L; Liu X; Zheng Q; Xu Z; Niu H
Curr Med Res Opin; 2022 Sep; 38(9):1499-1507. PubMed ID: 35855662
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
9. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
10. Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
Hennessy MA; Hamid M; Keegan NM; Corrigan L; Goggin C; Oo NM; Carrigan M; Mockler D; O'Donovan A; Horgan AM
BMC Cancer; 2022 Jan; 22(1):3. PubMed ID: 34980003
[TBL] [Abstract][Full Text] [Related]
11. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials.
Ludmir EB; Subbiah IM; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Mandel JJ; Fang P; Smith BD; Smith GL; Pinnix CC; Sedrak MS; Kimmick GG; Stinchcombe TE; Jagsi R; Thomas CR; Fuller CD; VanderWalde NA
J Geriatr Oncol; 2020 Apr; 11(3):451-454. PubMed ID: 31711757
[TBL] [Abstract][Full Text] [Related]
12. Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.
Zhu B; Liu Y; Li J; Ni Q; Yin Z; Zhu J; Chen K; Yang X
Front Pharmacol; 2022; 13():817065. PubMed ID: 35529441
[No Abstract] [Full Text] [Related]
13. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
Chen H; Zhou Y; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and trends of clinical studies primarily sponsored by China in WHO primary registries between 2009 and 2018: a cross-sectional survey.
Xu Y; Dong M; Liu X
BMJ Open; 2020 Nov; 10(11):e037262. PubMed ID: 33444176
[TBL] [Abstract][Full Text] [Related]
15. Participation of elderly patients in registration trials for oncology drug applications in Japan.
Yonemori K; Hirakawa A; Komiyama N; Kouno T; Ando M; Fujiwara Y; Urano T; Akagawa H; Maruyama H; Toyoshima S
Ann Oncol; 2010 Oct; 21(10):2112-2118. PubMed ID: 20332138
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China.
Suo T; Mahteme H; Qin XY
World J Gastroenterol; 2011 Feb; 17(8):1071-5. PubMed ID: 21448361
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
18. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
19. Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.
Zhang Z; Luo F; Cao J; Lu F; Zhang Y; Ma Y; Zeng K; Zhang L; Zhao H
J Hematol Oncol; 2021 Aug; 14(1):124. PubMed ID: 34399818
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
